Heron Therapeutics, Inc.
HRTXNext catalyst
F18 FBPA Injection
Solid Tumor
Get an email about HRTX's next catalysts
Track Heron Therapeutics (HRTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
HRTX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.03 | FQ end Sep/2026 | Call: tbd
F18 FBPA Injection Phase 2 Est. Readout
Estimated primary completion for F18 FBPA Injection trial (NCT07691775) in Solid Tumor. Topline data typically follows completion by weeks to months.
SourceHow HRTX's past catalysts played out
Market Overview
Stock performance and key metrics
HTX-011
Postoperative Pain
+/- Bupivacaine HCl
Analgesia
APF530
Nausea and Vomiting
Bupivacaine HCl
Postoperative Pain
HTX-034
Bunions
Bupivacaine HCI (Marcaine)
Postoperative Pain
aprepitant
Postoperative Pain
Bupivacaine HCI without epinephrine
Post-Operative Pain
Ketorolac
Postoperative Pain
HTX-011B
Postoperative Pain
B10 L-BPA Injection
Meningioma
MMA regimen
Postoperative Pain
F18 FBPA Injection
Solid Tumor
HTX-002
Postoperative Pain
HTX-034 high dose
Bunions
HTX-034 low dose
Bunions
HTX-009
Postoperative Pain
HTX-011A
Postoperative Pain
Bupivacaine HCl without epinephrine
Postoperative Pain
Bupivicaine HCl
Postoperative Pain
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HTX-011 | Phase 3 | Postoperative Pain | - | - |
+/- Bupivacaine HCl | Phase 3 | Analgesia | - | - |
APF530 | Phase 3 | Nausea and Vomiting | - | - |
Bupivacaine HCl | Phase 3 | Postoperative Pain | - | - |
HTX-034 | Phase 2 | Bunions | - | - |
Bupivacaine HCI (Marcaine) | Phase 2 | Postoperative Pain | - | - |
aprepitant | Phase 2 | Postoperative Pain | - | - |
Bupivacaine HCI without epinephrine | Phase 2 | Post-Operative Pain | - | - |
Ketorolac | Phase 2 | Postoperative Pain | - | - |
HTX-011B | Phase 2 | Postoperative Pain | - | - |
B10 L-BPA Injection | Phase 2 | Meningioma | - | - |
MMA regimen | Phase 2 | Postoperative Pain | - | - |
F18 FBPA Injection | Phase 2 | Solid Tumor | - | - |
HTX-002 | Phase 2 | Postoperative Pain | - | - |
HTX-034 high dose | Phase 2 | Bunions | - | - |
HTX-034 low dose | Phase 2 | Bunions | - | - |
HTX-009 | Phase 2 | Postoperative Pain | - | - |
HTX-011A | Phase 2 | Postoperative Pain | - | - |
Bupivacaine HCl without epinephrine | Phase 2 | Postoperative Pain | - | - |
Bupivicaine HCl | Phase 2 | Postoperative Pain | - | - |
Frequently asked questions
What is in Heron Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 20 drug candidates in Heron Therapeutics, Inc.'s (HRTX) pipeline across Phase 3, Phase 2. Its lead program is +/- Bupivacaine HCl (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Heron Therapeutics, Inc.'s next FDA catalyst?→
Heron Therapeutics, Inc.'s (HRTX) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HRTX biotech catalysts?→
Add HRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Heron Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.